{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:46:12Z","timestamp":1793893572201,"version":"4.8.0"},"reference-count":384,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005347","name":"American Association for the Study of Liver Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.eprac.2022.03.010","type":"journal-article","created":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T02:18:07Z","timestamp":1652321887000},"page":"528-562","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":991,"title":["American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings"],"prefix":"10.1016","volume":"28","author":[{"given":"Kenneth","family":"Cusi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Isaacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Barb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Basu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Caprio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Timothy","family":"Garvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangeeta","family":"Kashyap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey I.","family":"Mechanick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marialena","family":"Mouzaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Nadolsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary E.","family":"Rinella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam B.","family":"Vos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zobair","family":"Younossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.eprac.2022.03.010_bib1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.eprac.2022.03.010_bib2","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/hep.29721","article-title":"Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis","volume":"68","author":"Younossi","year":"2018","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.eprac.2022.03.010_bib3","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/hep.24376","article-title":"Endpoints and clinical trial design for nonalcoholic steatohepatitis","volume":"54","author":"Sanyal","year":"2011","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.eprac.2022.03.010_bib44","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.eprac.2022.03.010_bib4","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jhep.2021.02.034","article-title":"Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort","volume":"75","author":"Harrison","year":"2021","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.eprac.2022.03.010_bib5","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.eprac.2022.03.010_bib6","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s12072-018-09926-z","article-title":"Race\/ethnicity-based temporal changes in prevalence of nafld-related advanced fibrosis in the United States, 2005-2016","volume":"13","author":"Kim","year":"2019","journal-title":"Hepatol Int"},{"issue":"2","key":"10.1016\/j.eprac.2022.03.010_bib7","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.cgh.2015.08.010","article-title":"Trends in the burden of nonalcoholic fatty liver disease in a United States cohort of veterans","volume":"14","author":"Kanwal","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.eprac.2022.03.010_bib8","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2337\/dc20-1997","article-title":"Advanced liver fibrosis is common in patients with type 2 diabetes followed in the outpatient setting: the need for systematic screening","volume":"44","author":"Lomonaco","year":"2021","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.eprac.2022.03.010_bib9","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2337\/dc20-1778","article-title":"High prevalence of advanced liver fibrosis assessed by transient elastography among U.S. adults with type 2 diabetes","volume":"44","author":"Ciardullo","year":"2021","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.eprac.2022.03.010_bib10","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1002\/oby.23263","article-title":"Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease","volume":"29","author":"Barb","year":"2021","journal-title":"Obesity (Silver Spring)"},{"issue":"3","key":"10.1016\/j.eprac.2022.03.010_bib11","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1136\/gutjnl-2019-318813","article-title":"Epidemiology of chronic liver diseases in the USA in the past three decades","volume":"69","author":"Younossi","year":"2020","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.eprac.2022.03.010_bib12","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"Estes","year":"2018","journal-title":"Hepatology"},{"issue":"13","key":"10.1016\/j.eprac.2022.03.010_bib13","doi-asserted-by":"crossref","first-page":"e0214","DOI":"10.1097\/MD.0000000000010214","article-title":"Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD)","volume":"97","author":"Golabi","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"11","key":"10.1016\/j.eprac.2022.03.010_bib14","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1002\/hep4.1419","article-title":"Mortality related to nonalcoholic fatty liver disease is increasing in the United States","volume":"3","author":"Paik","year":"2019","journal-title":"Hepatol Commun"},{"issue":"5","key":"10.1016\/j.eprac.2022.03.010_bib15","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/hep.31173","article-title":"Changes in the global burden of chronic liver diseases from 2012 to 2017: the growing impact of NAFLD","volume":"72","author":"Paik","year":"2020","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.eprac.2022.03.010_bib16","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.cgh.2018.05.057","article-title":"Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates","volume":"17","author":"Younossi","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.eprac.2022.03.010_bib17","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jhep.2021.05.022","article-title":"Burden of non-alcoholic fatty liver disease in Asia, the Middle East and North Africa: data from global burden of disease 2009-2019","volume":"75","author":"Golabi","year":"2021","journal-title":"J\u00a0Hepatol"},{"issue":"11","key":"10.1016\/j.eprac.2022.03.010_bib18","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1002\/hep4.1765","article-title":"Poor awareness of liver disease among adults with NAFLD in the United States","volume":"5","author":"Alqahtani","year":"2021","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.eprac.2022.03.010_bib19","article-title":"A\u00a0global survey of physicians knowledge about nonalcoholic fatty liver disease","author":"Younossi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.eprac.2022.03.010_bib20","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.2337\/dci21-0020","article-title":"Preparing for the NASH epidemic: a call to action","volume":"44","author":"Kanwal","year":"2021","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.eprac.2022.03.010_bib21","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1053\/j.gastro.2021.07.049","article-title":"Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease","volume":"161","author":"Kanwal","year":"2021","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.eprac.2022.03.010_bib22","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41575-021-00477-7","article-title":"Defining comprehensive models of care for NAFLD","volume":"18","author":"Lazarus","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.eprac.2022.03.010_bib23","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1111\/liv.12840","article-title":"Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients","volume":"35","author":"Bril","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.eprac.2022.03.010_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-8587(22)00003-1","article-title":"A\u00a0global view of the interplay between non-alcoholic fatty liver disease and diabetes","author":"Stefan","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.eprac.2022.03.010_bib25","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/apt.13405","article-title":"Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE","volume":"43","author":"Doycheva","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.eprac.2022.03.010_bib26","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/MCG.0000000000000666","article-title":"The association between nonalcoholic fatty liver disease and metabolic abnormalities in the United States population","volume":"51","author":"Jinjuvadia","year":"2017","journal-title":"J\u00a0Clin Gastroenterol"},{"issue":"3","key":"10.1016\/j.eprac.2022.03.010_bib27","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/hep.31014","article-title":"Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in nonalcoholic fatty liver disease","volume":"71","author":"Kanwal","year":"2020","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.eprac.2022.03.010_bib28","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jhepr.2019.07.002","article-title":"From NASH to diabetes and from diabetes to NASH: mechanisms and treatment options","volume":"1","author":"Gastaldelli","year":"2019","journal-title":"JHEP Rep"},{"issue":"6","key":"10.1016\/j.eprac.2022.03.010_bib29","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1210\/jc.2015-1966","article-title":"High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels","volume":"100","author":"Portillo-Sanchez","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.eprac.2022.03.010_bib30","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.jhep.2014.11.034","article-title":"Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management","volume":"62","author":"McPherson","year":"2015","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.eprac.2022.03.010_bib31","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1002\/hep.31806","article-title":"Glycemic control predicts severity of hepatocyte ballooning and hepatic fibrosis in nonalcoholic fatty liver disease","volume":"74","author":"Alexopoulos","year":"2021","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.eprac.2022.03.010_bib32","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.cgh.2017.09.041","article-title":"Racial and ethnic disparities in nonalcoholic fatty liver disease prevalence, severity, and outcomes in the United States: a systematic review and meta-analysis","volume":"16","author":"Rich","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.eprac.2022.03.010_bib33","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/hep.24483","article-title":"Role of ethnicity in overweight and obese patients with nonalcoholic steatohepatitis","volume":"54","author":"Lomonaco","year":"2011","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.eprac.2022.03.010_bib34","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cmet.2019.12.002","article-title":"Leveraging human genetics to identify potential new treatments for fatty liver disease","volume":"31","author":"Romeo","year":"2020","journal-title":"Cell Metab"},{"issue":"12","key":"10.1016\/j.eprac.2022.03.010_bib35","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat Genet"},{"issue":"7","key":"10.1016\/j.eprac.2022.03.010_bib36","doi-asserted-by":"crossref","first-page":"763","DOI":"10.4254\/wjh.v13.i7.763","article-title":"Racial differences in prevalence and severity of non-alcoholic fatty liver disease","volume":"13","author":"Bonacini","year":"2021","journal-title":"World J Hepatol"},{"issue":"3","key":"10.1016\/j.eprac.2022.03.010_bib37","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/hep.31238","article-title":"Combined effect of PNPLA3, TM6SF2, and HSD17B13 variants on risk of cirrhosis and hepatocellular carcinoma in the general population","volume":"72","author":"Gellert-Kristensen","year":"2020","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.eprac.2022.03.010_bib38","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/ng.3855","article-title":"Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci","volume":"49","author":"Stender","year":"2017","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.eprac.2022.03.010_bib39","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jhep.2017.11.012","article-title":"Determinants of fibrosis progression and regression in NASH","volume":"68","author":"Schuppan","year":"2018","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.eprac.2022.03.010_bib40","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1053\/j.gastro.2018.04.034","article-title":"Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study","volume":"155","author":"Vilar-Gomez","year":"2018","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.eprac.2022.03.010_bib41","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jhep.2017.07.027","article-title":"Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD","volume":"67","author":"Hagstr\u00f6m","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.eprac.2022.03.010_bib42","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","article-title":"Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"158","author":"Taylor","year":"2020","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.eprac.2022.03.010_bib43","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1136\/gutjnl-2020-322786","article-title":"Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort","volume":"70","author":"Simon","year":"2021","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.eprac.2022.03.010_bib45","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jceh.2019.11.004","article-title":"Diabetes and hepatocellular carcinoma: incidence trends and impact of liver disease etiology","volume":"10","author":"Doycheva","year":"2020","journal-title":"J\u00a0Clin Exp Hepatol"},{"issue":"5","key":"10.1016\/j.eprac.2022.03.010_bib46","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1002\/hep.31845","article-title":"Cancer risk in patients with biopsy-confirmed nonalcoholic fatty liver disease: a population-based cohort study","volume":"74","author":"Simon","year":"2021","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.eprac.2022.03.010_bib47","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up","volume":"61","author":"Ekstedt","year":"2015","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.eprac.2022.03.010_bib48","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1053\/j.gastro.2007.04.068","article-title":"Relationship between hepatic\/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects","volume":"133","author":"Gastaldelli","year":"2007","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.eprac.2022.03.010_bib49","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1111\/liv.15005","article-title":"PPAR-\u03b3-induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH","volume":"41","author":"Gastaldelli","year":"2021","journal-title":"Liver Int"},{"issue":"4","key":"10.1016\/j.eprac.2022.03.010_bib50","doi-asserted-by":"crossref","first-page":"632","DOI":"10.2337\/dc15-1876","article-title":"Metabolic impact of nonalcoholic steatohepatitis in obese patients with type 2 diabetes","volume":"39","author":"Lomonaco","year":"2016","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.eprac.2022.03.010_bib51","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/jgh.13264","article-title":"Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis","volume":"31","author":"Ballestri","year":"2016","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.eprac.2022.03.010_bib52","doi-asserted-by":"crossref","first-page":"372","DOI":"10.2337\/dc17-1902","article-title":"Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis","volume":"41","author":"Mantovani","year":"2018","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.eprac.2022.03.010_bib53","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/liv.13994","article-title":"Causality between non-alcoholic fatty liver disease and risk of cardiovascular disease and type 2 diabetes: a meta-analysis with bias analysis","volume":"39","author":"Morrison","year":"2019","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.eprac.2022.03.010_bib54","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2337\/dc19-1113","article-title":"Economic and clinical burden of nonalcoholic steatohepatitis in patients with type 2 diabetes in the U.S","volume":"43","author":"Younossi","year":"2020","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.eprac.2022.03.010_bib55","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1210\/er.2017-00191","article-title":"Obesity in type 1 diabetes: pathophysiology, clinical impact, and mechanisms","volume":"39","author":"Corbin","year":"2018","journal-title":"Endocr Rev"},{"issue":"12","key":"10.1016\/j.eprac.2022.03.010_bib56","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.1210\/clinem\/dgaa575","article-title":"Prevalence of nonalcoholic fatty liver disease (NAFLD) in patients with type 1 diabetes mellitus: a systematic review and meta-analysis","volume":"105","author":"de Vries","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.eprac.2022.03.010_bib57","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1111\/dom.12973","article-title":"Non-alcoholic fatty liver disease (NAFLD) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes","volume":"19","author":"Cusi","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.eprac.2022.03.010_bib58","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrendo.2017.173","article-title":"Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus","volume":"14","author":"Targher","year":"2018","journal-title":"Nat Rev Endocrinol"},{"issue":"9","key":"10.1016\/j.eprac.2022.03.010_bib59","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/s41575-021-00448-y","article-title":"The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments","volume":"18","author":"Targher","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.eprac.2022.03.010_bib60","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/MOL.0000000000000717","article-title":"Cardiovascular risk in patients with nonalcoholic fatty liver disease: looking at the liver to shield the heart","volume":"31","author":"Cusi","year":"2020","journal-title":"Curr Opin Lipidol"},{"issue":"4","key":"10.1016\/j.eprac.2022.03.010_bib61","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3390\/ijms17040562","article-title":"NAFLD and chronic kidney disease","volume":"17","author":"Marcuccilli","year":"2016","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.eprac.2022.03.010_bib62","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.jhep.2020.01.013","article-title":"NAFLD as a driver of chronic kidney disease","volume":"72","author":"Byrne","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"7","key":"10.1016\/j.eprac.2022.03.010_bib63","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001680","article-title":"Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis","volume":"11","author":"Musso","year":"2014","journal-title":"PLoS Med"},{"key":"10.1016\/j.eprac.2022.03.010_bib64","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.metabol.2017.11.003","article-title":"Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: a systematic review and meta-analysis","volume":"79","author":"Mantovani","year":"2018","journal-title":"Metabolism"},{"issue":"8","key":"10.1016\/j.eprac.2022.03.010_bib65","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1111\/jdi.13489","article-title":"Association of non-alcoholic fatty liver disease with diabetic retinopathy in type 2 diabetic patients: a meta-analysis of observational studies","volume":"12","author":"Song","year":"2021","journal-title":"J\u00a0Diabetes Investig"},{"issue":"3","key":"10.1016\/j.eprac.2022.03.010_bib66","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002542","article-title":"Polycystic ovary syndrome, androgen excess, and the risk of nonalcoholic fatty liver disease in women: a longitudinal study based on a United Kingdom primary care database","volume":"15","author":"Kumarendran","year":"2018","journal-title":"PLoS Med"},{"issue":"2","key":"10.1016\/j.eprac.2022.03.010_bib67","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/liv.14279","article-title":"Polycystic ovary syndrome (PCOS) is associated with NASH severity and advanced fibrosis","volume":"40","author":"Sarkar","year":"2020","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.eprac.2022.03.010_bib68","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1210\/clinem\/dgab658","article-title":"Nonalcoholic fatty liver disease in women and girls with polycystic ovary syndrome","volume":"107","author":"Falzarano","year":"2022","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.eprac.2022.03.010_bib69","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1530\/EJE-15-0567","article-title":"Increased prevalence of polycystic ovary syndrome in premenopausal women with nonalcoholic fatty liver disease","volume":"173","author":"Vassilatou","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.eprac.2022.03.010_bib70","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12978-018-0519-2","article-title":"A\u00a0potential link between polycystic ovary syndrome and non-alcoholic fatty liver disease: an update meta-analysis","volume":"15","author":"Wu","year":"2018","journal-title":"Reprod Health"},{"issue":"4","key":"10.1016\/j.eprac.2022.03.010_bib71","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.dld.2018.12.014","article-title":"Pathogenesis of hypothyroidism-induced NAFLD: evidence for a distinct disease entity?","volume":"51","author":"Lonardo","year":"2019","journal-title":"Dig Liver Dis"},{"issue":"10","key":"10.1016\/j.eprac.2022.03.010_bib72","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1089\/thy.2018.0257","article-title":"Association between primary hypothyroidism and nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"28","author":"Mantovani","year":"2018","journal-title":"Thyroid"},{"issue":"3","key":"10.1016\/j.eprac.2022.03.010_bib73","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1089\/thy.2018.0622","article-title":"Re: \u201cAssociation between primary hypothyroidism and nonalcoholic fatty liver disease: a systematic review and meta-analysis\u201d by Mantovani et\u00a0al. (Thyroid 2018;28:1270-1284)","volume":"29","author":"Bril","year":"2019","journal-title":"Thyroid"},{"issue":"1","key":"10.1016\/j.eprac.2022.03.010_bib74","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1136\/jim-2015-000019","article-title":"Plasma thyroid hormone concentration is associated with hepatic triglyceride content in patients with type 2 diabetes","volume":"64","author":"Bril","year":"2016","journal-title":"J\u00a0Investig Med"},{"key":"10.1016\/j.eprac.2022.03.010_bib75","doi-asserted-by":"crossref","first-page":"294278","DOI":"10.1155\/2015\/294278","article-title":"Sex hormones and their receptors regulate liver energy homeostasis","volume":"2015","author":"Shen","year":"2015","journal-title":"Int J Endocrinol"},{"issue":"6","key":"10.1016\/j.eprac.2022.03.010_bib76","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0251449","article-title":"Severity of non-alcoholic steatohepatitis is not linked to testosterone concentration in patients with type 2 diabetes","volume":"16","author":"Dayton","year":"2021","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.eprac.2022.03.010_bib77","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.3390\/ijms19051308","article-title":"Insulin-like growth factor (IGF) system in liver diseases","volume":"19","author":"Adamek","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"7","key":"10.1016\/j.eprac.2022.03.010_bib78","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/hepr.12408","article-title":"Lower levels of insulin-like growth factor-1 standard deviation score are associated with histological severity of non-alcoholic fatty liver disease","volume":"45","author":"Sumida","year":"2015","journal-title":"Hepatol Res"},{"issue":"1","key":"10.1016\/j.eprac.2022.03.010_bib79","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1530\/EJE-12-0252","article-title":"Nonalcoholic fatty liver disease in adult hypopituitary patients with GH deficiency and the impact of GH replacement therapy","volume":"167","author":"Nishizawa","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.eprac.2022.03.010_bib80","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s12020-019-01982-1","article-title":"Insulin-like growth factor-1 and non-alcoholic fatty liver disease: a systemic review and meta-analysis","volume":"65","author":"Yao","year":"2019","journal-title":"Endocrine"},{"issue":"22","key":"10.1016\/j.eprac.2022.03.010_bib81","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1001\/jama.2015.5370","article-title":"Nonalcoholic fatty liver disease: a systematic review","volume":"313","author":"Rinella","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.eprac.2022.03.010_bib82","series-title":"Endotext","article-title":"Nonalcoholic fatty liver disease: the overlooked complication of type 2 diabetes","author":"Akshintala","year":"2000"},{"issue":"2","key":"10.1016\/j.eprac.2022.03.010_bib83","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jhep.2015.02.045","article-title":"Hepatic steatosis and cardiovascular disease outcomes: an analysis of the Framingham Heart study","volume":"63","author":"Mellinger","year":"2015","journal-title":"J\u00a0Hepatol"},{"issue":"9","key":"10.1016\/j.eprac.2022.03.010_bib84","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1136\/gutjnl-2020-320622","article-title":"NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications","volume":"69","author":"Targher","year":"2020","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.eprac.2022.03.010_bib85","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.jhep.2017.12.012","article-title":"Association between non-alcoholic fatty liver disease and subclinical coronary atherosclerosis: an observational cohort study","volume":"68","author":"Lee","year":"2018","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.eprac.2022.03.010_bib86","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/liv.13973","article-title":"Cardiovascular risk factors in non-alcoholic fatty liver disease","volume":"39","author":"Hagstr\u00f6m","year":"2019","journal-title":"Liver Int"},{"issue":"8","key":"10.1016\/j.eprac.2022.03.010_bib87","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S2468-1253(20)30077-7","article-title":"Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"5","author":"Ye","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.eprac.2022.03.010_bib88","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/liv.14044","article-title":"Association between non-alcoholic fatty liver disease and risk of atrial fibrillation in adult individuals: an updated meta-analysis","volume":"39","author":"Mantovani","year":"2019","journal-title":"Liver Int"},{"issue":"8","key":"10.1016\/j.eprac.2022.03.010_bib89","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.2337\/dc16-0091","article-title":"Nonalcoholic fatty liver disease is associated with ventricular arrhythmias in patients with type 2 diabetes referred for clinically indicated 24-hour holter monitoring","volume":"39","author":"Mantovani","year":"2016","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.eprac.2022.03.010_bib90","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.dld.2018.09.004","article-title":"Association between diastolic cardiac dysfunction and nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"50","author":"Wijarnpreecha","year":"2018","journal-title":"Dig Liver Dis"},{"issue":"8","key":"10.1016\/j.eprac.2022.03.010_bib91","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1007\/s10620-016-4125-2","article-title":"Significant association between gallstone disease and nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"61","author":"Jaruvongvanich","year":"2016","journal-title":"Dig Dis Sci"},{"issue":"5","key":"10.1016\/j.eprac.2022.03.010_bib92","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/obr.12020","article-title":"Association of obstructive sleep apnoea with the presence and severity of non-alcoholic fatty liver disease. A systematic review and meta-analysis","volume":"14","author":"Musso","year":"2013","journal-title":"Obes Rev"},{"issue":"9","key":"10.1016\/j.eprac.2022.03.010_bib93","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1111\/liv.14163","article-title":"Nonalcoholic steatohepatitis is associated with a higher risk of advanced colorectal neoplasm","volume":"39","author":"Cho","year":"2019","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.eprac.2022.03.010_bib94","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jhep.2016.08.019","article-title":"Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis","volume":"66","author":"Koo","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.eprac.2022.03.010_bib95","doi-asserted-by":"crossref","first-page":"584","DOI":"10.14309\/ajg.0000000000000572","article-title":"Nonalcoholic fatty liver disease and sarcopenia are independently associated with cardiovascular risk","volume":"115","author":"Han","year":"2020","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.eprac.2022.03.010_bib96","doi-asserted-by":"crossref","first-page":"100171","DOI":"10.1016\/j.jhepr.2020.100171","article-title":"Contribution of sarcopenia and physical inactivity to mortality in people with non-alcoholic fatty liver disease","volume":"2","author":"Golabi","year":"2020","journal-title":"JHEP Rep"},{"issue":"18","key":"10.1016\/j.eprac.2022.03.010_bib97","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.eprac.2022.03.010_bib98","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann Intern Med"},{"issue":"12","key":"10.1016\/j.eprac.2022.03.010_bib99","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A\u00a0placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.eprac.2022.03.010_bib100","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.4158\/EP171866.GL","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology protocol for standardized production of clinical practice guidelines, algorithms, and checklists - 2017 update","volume":"23","author":"Mechanick","year":"2017","journal-title":"Endocr Pract"},{"issue":"1","key":"10.1016\/j.eprac.2022.03.010_bib101","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.eprac.2022.03.010_bib102","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1111\/jgh.14577","article-title":"Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography","volume":"34","author":"Lai","year":"2019","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.eprac.2022.03.010_bib103","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1111\/liv.13397","article-title":"Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: an age-dependent risk profiling study","volume":"37","author":"Petta","year":"2017","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.eprac.2022.03.010_bib104","doi-asserted-by":"crossref","first-page":"290","DOI":"10.2337\/dc19-1071","article-title":"Performance of plasma biomarkers and diagnostic panels for nonalcoholic steatohepatitis and advanced fibrosis in patients with type 2 diabetes","volume":"43","author":"Bril","year":"2020","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.eprac.2022.03.010_bib105","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/apt.14327","article-title":"Significant burden of nonalcoholic fatty liver disease with advanced fibrosis in the US: a cross-sectional analysis of 2011-2014 national health and nutrition examination survey","volume":"46","author":"Wong","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.eprac.2022.03.010_bib106","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.jhep.2018.08.013","article-title":"The conundrum of cryptogenic cirrhosis: adverse outcomes without treatment options","volume":"69","author":"Younossi","year":"2018","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.eprac.2022.03.010_bib107","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-137-1-200207020-00006","article-title":"Updated definitions of healthy ranges for serum alanine aminotransferase levels","volume":"137","author":"Prati","year":"2002","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.eprac.2022.03.010_bib108","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/ajg.2016.517","article-title":"ACG clinical guideline: evaluation of abnormal liver chemistries","volume":"112","author":"Kwo","year":"2017","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.eprac.2022.03.010_bib109","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/hep.27395","article-title":"The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease","volume":"61","author":"Maximos","year":"2015","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.eprac.2022.03.010_bib110","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1136\/gutjnl-2015-309265","article-title":"Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study","volume":"65","author":"Kwok","year":"2016","journal-title":"Gut"},{"issue":"12","key":"10.1016\/j.eprac.2022.03.010_bib111","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1111\/liv.13481","article-title":"Concomitant screening for liver fibrosis and steatosis in French type 2 diabetic patients using FibroScan","volume":"37","author":"Roulot","year":"2017","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.eprac.2022.03.010_bib112","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.eprac.2022.03.010_bib113","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1053\/j.gastro.2020.07.050","article-title":"Screening for nonalcoholic fatty liver disease in persons with type 2 diabetes in the United States is cost-effective: a comprehensive cost-utility analysis","volume":"159","author":"Noureddin","year":"2020","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.eprac.2022.03.010_bib114","first-page":"1032","article-title":"Screening for liver fibrosis and steatosis in a large cohort of patients with type 2 diabetes using vibration controlled transient elastography and controlled attenuation parameter in a single-center real-life experience","volume":"9","author":"Sporea","year":"2020","journal-title":"J\u00a0Clin Med"},{"issue":"1","key":"10.1016\/j.eprac.2022.03.010_bib115","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/liv.13970","article-title":"Reducing NAFLD-screening time: a comparative study of eight diagnostic methods offering an alternative to ultrasound scans","volume":"39","author":"Procino","year":"2019","journal-title":"Liver Int"},{"issue":"11","key":"10.1016\/j.eprac.2022.03.010_bib116","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1001\/jamasurg.2016.2317","article-title":"Bariatric surgery and long-term durability of weight loss","volume":"151","author":"Maciejewski","year":"2016","journal-title":"JAMA Surg"},{"issue":"22","key":"10.1016\/j.eprac.2022.03.010_bib117","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1001\/jama.2014.5988","article-title":"Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications","volume":"311","author":"Sj\u00f6str\u00f6m","year":"2014","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.eprac.2022.03.010_bib118","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1056\/NEJMoa1600869","article-title":"Bariatric surgery versus intensive medical therapy for diabetes - 5-year outcomes","volume":"376","author":"Schauer","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.eprac.2022.03.010_bib119","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/apt.12569","article-title":"Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease--the role of transient elastography and plasma cytokeratin-18 fragments","volume":"39","author":"Kwok","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.eprac.2022.03.010_bib120","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1007\/s11695-016-2144-x","article-title":"Effects of bariatric surgery on mortality, cardiovascular events, and cancer outcomes in obese patients: systematic review and meta-analysis","volume":"26","author":"Zhou","year":"2016","journal-title":"Obes Surg"},{"issue":"7","key":"10.1016\/j.eprac.2022.03.010_bib121","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003206","article-title":"Association of bariatric surgery with all-cause mortality and incidence of obesity-related disease at a population level: a systematic review and meta-analysis","volume":"17","author":"Wiggins","year":"2020","journal-title":"PLoS Med"},{"issue":"3","key":"10.1016\/j.eprac.2022.03.010_bib122","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.soard.2018.12.002","article-title":"Bariatric surgery improves nonalcoholic fatty liver disease: a contemporary systematic review and meta-analysis","volume":"15","author":"Fakhry","year":"2019","journal-title":"Surg Obes Relat Dis"},{"issue":"6","key":"10.1016\/j.eprac.2022.03.010_bib123","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.cgh.2018.10.017","article-title":"Complete resolution of nonalcoholic fatty liver disease after bariatric surgery: a systematic review and meta-analysis","volume":"17","author":"Lee","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.eprac.2022.03.010_bib124","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/apt.16335","article-title":"Systematic review with meta-analysis: bariatric surgery reduces the incidence of hepatocellular carcinoma","volume":"53","author":"Ramai","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.eprac.2022.03.010_bib125","doi-asserted-by":"crossref","first-page":"5023157","DOI":"10.1155\/2020\/5023157","article-title":"The prevalence of NAFLD and fibrosis in bariatric surgery patients and the reliability of noninvasive diagnostic methods","volume":"2020","author":"Soresi","year":"2020","journal-title":"Biomed Res Int"},{"issue":"1","key":"10.1016\/j.eprac.2022.03.010_bib126","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s11695-015-1916-z","article-title":"Routine liver biopsy during bariatric surgery: an analysis of evidence base","volume":"26","author":"Mahawar","year":"2016","journal-title":"Obes Surg"},{"issue":"3","key":"10.1016\/j.eprac.2022.03.010_bib127","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.soard.2020.11.004","article-title":"Safety of metabolic and bariatric surgery in obese patients with liver cirrhosis: a systematic review and meta-analysis","volume":"17","author":"Agarwal","year":"2021","journal-title":"Surg Obes Relat Dis"},{"issue":"10","key":"10.1016\/j.eprac.2022.03.010_bib128","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.14309\/ajg.0000000000000388","article-title":"Histologic findings of advanced fibrosis and cirrhosis in patients with nonalcoholic fatty liver disease who have normal aminotransferase levels","volume":"114","author":"Gawrieh","year":"2019","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.eprac.2022.03.010_bib129","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/hep.24452","article-title":"Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis","volume":"54","author":"Hernaez","year":"2011","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.eprac.2022.03.010_bib130","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/hep.29302","article-title":"Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis","volume":"66","author":"Xiao","year":"2017","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.eprac.2022.03.010_bib131","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/hep.28337","article-title":"Magnetic resonance elastography is superior to acoustic radiation force impulse for the diagnosis of fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease: a prospective study","volume":"63","author":"Cui","year":"2016","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.eprac.2022.03.010_bib132","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1148\/radiol.2016160685","article-title":"Diagnostic performance of MR elastography and vibration-controlled transient elastography in the detection of hepatic fibrosis in patients with severe to morbid obesity","volume":"283","author":"Chen","year":"2017","journal-title":"Radiology"},{"issue":"3","key":"10.1016\/j.eprac.2022.03.010_bib133","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1053\/j.gastro.2015.11.048","article-title":"Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography","volume":"150","author":"Imajo","year":"2016","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.eprac.2022.03.010_bib134","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","article-title":"Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease","volume":"156","author":"Castera","year":"2019","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.eprac.2022.03.010_bib135","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/j.cgh.2018.12.031","article-title":"Diagnostic accuracy of noninvasive fibrosis models to detect change in fibrosis stage","volume":"17","author":"Siddiqui","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.eprac.2022.03.010_bib136","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/hep.29113","article-title":"Liver fibrosis scores predict liver disease mortality in the United States population","volume":"66","author":"Unalp-Arida","year":"2017","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.eprac.2022.03.010_bib137","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/liv.14669","article-title":"Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: a systematic review","volume":"41","author":"Lee","year":"2021","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.eprac.2022.03.010_bib138","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.jhep.2013.10.017","article-title":"Using non-invasive biomarkers to identify hepatic fibrosis in people with type 2 diabetes mellitus: the Edinburgh type 2 diabetes study","volume":"60","author":"Morling","year":"2014","journal-title":"J\u00a0Hepatol"},{"issue":"8","key":"10.1016\/j.eprac.2022.03.010_bib139","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1111\/jgh.14559","article-title":"Distribution of liver stiffness in non-alcoholic fatty liver disease with higher fibrosis-4 index than low cut-off index","volume":"34","author":"Tomeno","year":"2019","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.eprac.2022.03.010_bib140","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.jhep.2019.04.020","article-title":"New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD","volume":"71","author":"Boursier","year":"2019","journal-title":"J\u00a0Hepatol"},{"issue":"11","key":"10.1016\/j.eprac.2022.03.010_bib141","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S2468-1253(20)30252-1","article-title":"A\u00a0blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study","volume":"5","author":"Harrison","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.eprac.2022.03.010_bib142","first-page":"dgab933","article-title":"Obesity modifies the performance of fibrosis biomarkers in nonalcoholic fatty liver disease","author":"Qadri","year":"2021","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.eprac.2022.03.010_bib143","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jhep.2020.03.036","article-title":"Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: a systematic review and meta-analysis","volume":"73","author":"Vali","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"7","key":"10.1016\/j.eprac.2022.03.010_bib144","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.2337\/dc18-2578","article-title":"Use of plasma fragments of propeptides of type III, V, and VI procollagen for the detection of liver fibrosis in type 2 diabetes","volume":"42","author":"Bril","year":"2019","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.eprac.2022.03.010_bib145","doi-asserted-by":"crossref","first-page":"100355","DOI":"10.1016\/j.jhepr.2021.100355","article-title":"Biomarkers of extracellular matrix formation are associated with acute-on-chronic liver failure","volume":"3","author":"Kerbert","year":"2021","journal-title":"JHEP Rep"},{"issue":"4","key":"10.1016\/j.eprac.2022.03.010_bib146","doi-asserted-by":"crossref","first-page":"100317","DOI":"10.1016\/j.jhepr.2021.100317","article-title":"Determining a healthy reference range and factors potentially influencing PRO-C3 - a biomarker of liver fibrosis","volume":"3","author":"Erhardtsen","year":"2021","journal-title":"JHEP Rep"},{"issue":"3","key":"10.1016\/j.eprac.2022.03.010_bib147","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2337\/dc16-1787","article-title":"Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action","volume":"40","author":"Bril","year":"2017","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.eprac.2022.03.010_bib148","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1053\/j.gastro.2020.12.003","article-title":"The association of histologic and noninvasive tests with adverse clinical and patient-reported outcomes in patients with advanced fibrosis due to nonalcoholic steatohepatitis","volume":"160","author":"Younossi","year":"2021","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.eprac.2022.03.010_bib149","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/s41575-021-00502-9","article-title":"Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests","volume":"18","author":"Masoodi","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.eprac.2022.03.010_bib150","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/hep.30842","article-title":"Noninvasive tests accurately identify advanced fibrosis due to NASH: baseline data from the stellar trials","volume":"70","author":"Anstee","year":"2019","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.eprac.2022.03.010_bib151","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1097\/MCG.0000000000001339","article-title":"Accuracy of noninvasive fibrosis scores to detect advanced fibrosis in patients with type-2 diabetes with biopsy-proven nonalcoholic fatty liver disease","volume":"54","author":"Singh","year":"2020","journal-title":"J\u00a0Clin Gastroenterol"},{"issue":"1","key":"10.1016\/j.eprac.2022.03.010_bib152","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/jgh.13814","article-title":"Fatty liver index and hepatic steatosis index for prediction of non-alcoholic fatty liver disease in type 1 diabetes","volume":"33","author":"Svikl\u0101ne","year":"2018","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.eprac.2022.03.010_bib153","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1016\/j.cgh.2019.03.006","article-title":"Optimizing use of nonalcoholic fatty liver disease fibrosis score, fibrosis-4 score, and liver stiffness measurement to identify patients with advanced fibrosis","volume":"17","author":"Chan","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.eprac.2022.03.010_bib154","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1007\/s00535-018-1474-y","article-title":"The novel cutoff points for the FIB4 index categorized by age increase the diagnostic accuracy in NAFLD: a multi-center study","volume":"53","author":"Ishiba","year":"2018","journal-title":"J\u00a0Gastroenterol"},{"issue":"5","key":"10.1016\/j.eprac.2022.03.010_bib155","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/ajg.2016.453","article-title":"Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis","volume":"112","author":"McPherson","year":"2017","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.eprac.2022.03.010_bib156","doi-asserted-by":"crossref","first-page":"916","DOI":"10.14309\/ajg.0000000000000153","article-title":"Impact of obesity and alanine aminotransferase levels on the diagnostic accuracy for advanced liver fibrosis of noninvasive tools in patients with nonalcoholic fatty liver disease","volume":"114","author":"Petta","year":"2019","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.eprac.2022.03.010_bib157","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.jhep.2020.06.025","article-title":"Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials","volume":"73","author":"Davison","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.eprac.2022.03.010_bib158","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.cgh.2018.04.043","article-title":"Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease","volume":"17","author":"Siddiqui","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.eprac.2022.03.010_bib159","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1053\/j.gastro.2019.01.042","article-title":"Accuracy of fibroscan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease","volume":"156","author":"Eddowes","year":"2019","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.eprac.2022.03.010_bib160","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.cgh.2018.08.069","article-title":"Range of normal liver stiffness and factors associated with increased stiffness measurements in apparently healthy individuals","volume":"17","author":"Bazerbachi","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.eprac.2022.03.010_bib161","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1007\/s10620-017-4638-3","article-title":"Controlled attenuation parameter (CAP) with the XL probe of the FibroScan \u00ae: a comparative study with the M probe and liver biopsy","volume":"62","author":"de L\u00e9dinghen","year":"2017","journal-title":"Dig Dis Sci"},{"issue":"3","key":"10.1016\/j.eprac.2022.03.010_bib162","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S2468-1253(20)30357-5","article-title":"Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis","volume":"6","author":"Petroff","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.eprac.2022.03.010_bib163","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jhep.2020.11.050","article-title":"Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease","volume":"74","author":"Papatheodoridi","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.eprac.2022.03.010_bib164","article-title":"Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis","author":"M\u00f3zes","year":"2021","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.eprac.2022.03.010_bib165","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.jhep.2021.04.044","article-title":"Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: a systematic review and meta-analysis","volume":"75","author":"Selvaraj","year":"2021","journal-title":"J\u00a0Hepatol"},{"issue":"12","key":"10.1016\/j.eprac.2022.03.010_bib166","doi-asserted-by":"crossref","first-page":"6477","DOI":"10.1007\/s00330-019-06331-4","article-title":"Prospective comparison of transient, point shear wave, and magnetic resonance elastography for staging liver fibrosis","volume":"29","author":"Lefebvre","year":"2019","journal-title":"Eur Radiol"},{"issue":"8","key":"10.1016\/j.eprac.2022.03.010_bib167","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-021787","article-title":"Diagnostic accuracy of point shear wave elastography and transient elastography for staging hepatic fibrosis in patients with non-alcoholic fatty liver disease: a meta-analysis","volume":"8","author":"Jiang","year":"2018","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.eprac.2022.03.010_bib168","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1109\/TMI.2020.3034065","article-title":"Three-dimensional multi-frequency shear wave absolute vibro-elastography (3D S-WAVE) with a matrix array transducer: implementation and preliminary in\u00a0vivo study of the liver","volume":"40","author":"Zeng","year":"2021","journal-title":"IEEE Trans Med Imaging"},{"key":"10.1016\/j.eprac.2022.03.010_bib169","doi-asserted-by":"crossref","first-page":"100158","DOI":"10.1016\/j.metop.2021.100158","article-title":"Noninvasive assessment of fibrosis among patients with nonalcoholic fatty liver disease [NAFLD]","volume":"13","author":"Bernstein","year":"2022","journal-title":"Metabol Open"},{"issue":"4","key":"10.1016\/j.eprac.2022.03.010_bib170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0249491","article-title":"Comparison between magnetic resonance and ultrasound-derived indicators of hepatic steatosis in a pooled NAFLD cohort","volume":"16","author":"Beyer","year":"2021","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.eprac.2022.03.010_bib171","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/apt.14469","article-title":"Utility and cost evaluation of multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease","volume":"47","author":"Eddowes","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.eprac.2022.03.010_bib172","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1111\/liv.14625","article-title":"Prognostic value of multiparametric magnetic resonance imaging, transient elastography and blood-based fibrosis markers in patients with chronic liver disease","volume":"40","author":"Jayaswal","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.eprac.2022.03.010_bib173","doi-asserted-by":"crossref","first-page":"575843","DOI":"10.3389\/fendo.2020.575843","article-title":"Correlations between MRI biomarkers PDFF and CT1 with histopathological features of non-alcoholic steatohepatitis","volume":"11","author":"Dennis","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"11","key":"10.1016\/j.eprac.2022.03.010_bib174","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11892-020-01349-1","article-title":"Role of agents for the treatment of diabetes in the management of nonalcoholic fatty liver disease","volume":"20","author":"Budd","year":"2020","journal-title":"Curr Diab Rep"},{"issue":"4","key":"10.1016\/j.eprac.2022.03.010_bib175","doi-asserted-by":"crossref","first-page":"873","DOI":"10.2337\/dc11-1849","article-title":"Prevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease (NAFLD)","volume":"35","author":"Ortiz-Lopez","year":"2012","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.eprac.2022.03.010_bib176","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/hep.27098","article-title":"Prevalence and natural history of histologically proven chronic liver disease in a longitudinal cohort of patients with type 1 diabetes","volume":"60","author":"Harman","year":"2014","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.eprac.2022.03.010_bib177","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jdiacomp.2007.02.005","article-title":"Effect of insulin-metformin combination on hepatic steatosis in patients with type 2 diabetes","volume":"21","author":"Lingvay","year":"2007","journal-title":"J\u00a0Diabetes Complications"},{"issue":"3","key":"10.1016\/j.eprac.2022.03.010_bib178","doi-asserted-by":"crossref","first-page":"E829","DOI":"10.1152\/ajpendo.00133.2006","article-title":"Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes","volume":"292","author":"Juurinen","year":"2007","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.eprac.2022.03.010_bib179","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s40618-019-01031-8","article-title":"Vitamin D status and non-alcoholic fatty liver disease in patients with type 1 diabetes","volume":"42","author":"Cipponeri","year":"2019","journal-title":"J\u00a0Endocrinol Invest"},{"issue":"5","key":"10.1016\/j.eprac.2022.03.010_bib180","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.dld.2011.12.005","article-title":"Screening for liver fibrosis by using FibroScan(\u00ae) and FibroTest in patients with diabetes","volume":"44","author":"de L\u00e9dinghen","year":"2012","journal-title":"Dig Liver Dis"},{"issue":"4","key":"10.1016\/j.eprac.2022.03.010_bib181","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.jhep.2010.04.030","article-title":"Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes","volume":"53","author":"Targher","year":"2010","journal-title":"J\u00a0Hepatol"},{"issue":"12","key":"10.1016\/j.eprac.2022.03.010_bib182","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.4158\/EP14044.OR","article-title":"Clinical profile of nonalcoholic fatty liver disease among young patients with type 1 diabetes mellitus seen at a diabetes speciality center in India","volume":"20","author":"Vendhan","year":"2014","journal-title":"Endocr Pract"},{"key":"10.1016\/j.eprac.2022.03.010_bib183","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ijcard.2016.10.040","article-title":"Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular disease in adult patients with type 1 diabetes","volume":"225","author":"Mantovani","year":"2016","journal-title":"Int J Cardiol"},{"issue":"12","key":"10.1016\/j.eprac.2022.03.010_bib184","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa1010949","article-title":"Pioglitazone for diabetes prevention in impaired glucose tolerance","volume":"364","author":"DeFronzo","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"5-6","key":"10.1016\/j.eprac.2022.03.010_bib185","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s11357-016-9946-6","article-title":"Pioglitazone is equally effective for diabetes prevention in older versus younger adults with impaired glucose tolerance","volume":"38","author":"Espinoza","year":"2016","journal-title":"Age (Dordr)"},{"issue":"14","key":"10.1016\/j.eprac.2022.03.010_bib186","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1506930","article-title":"Pioglitazone after ischemic stroke or transient ischemic attack","volume":"374","author":"Kernan","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.eprac.2022.03.010_bib187","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.2337\/dc16-0798","article-title":"Pioglitazone prevents diabetes in patients with insulin resistance and cerebrovascular disease","volume":"39","author":"Inzucchi","year":"2016","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.eprac.2022.03.010_bib188","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0236977","article-title":"Clinical spectrum of non-alcoholic fatty liver\u00a0disease in patients with diabetes mellitus","volume":"15","author":"Chen","year":"2020","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.eprac.2022.03.010_bib189","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/hep.27981","article-title":"Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: the Rotterdam study","volume":"63","author":"Koehler","year":"2016","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.eprac.2022.03.010_bib190","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.diabet.2019.11.004","article-title":"Screening for non-alcoholic fatty liver disease using liver stiffness measurement and its association with chronic kidney disease and cardiovascular complications in patients with type 2 diabetes","volume":"46","author":"Mantovani","year":"2020","journal-title":"Diabetes Metab"},{"issue":"6","key":"10.1016\/j.eprac.2022.03.010_bib191","doi-asserted-by":"crossref","first-page":"e3157","DOI":"10.1002\/dmrr.3157","article-title":"Prevalence of diabetes in liver cirrhosis: a systematic review and meta-analysis","volume":"35","author":"Lee","year":"2019","journal-title":"Diabetes Metab Res Rev"},{"issue":"4","key":"10.1016\/j.eprac.2022.03.010_bib192","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1136\/flgastro-2018-101155","article-title":"A\u00a0multidisciplinary approach to the\u00a0management of NAFLD is associated with improvement in markers of liver and cardio-metabolic health","volume":"10","author":"Moolla","year":"2019","journal-title":"Frontline Gastroenterol"},{"issue":"4","key":"10.1016\/j.eprac.2022.03.010_bib193","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/hep.31142","article-title":"Serial transient elastography examinations to monitor patients with type 2 diabetes: a prospective cohort study","volume":"72","author":"Lee","year":"2020","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.eprac.2022.03.010_bib194","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jhep.2019.03.033","article-title":"Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease","volume":"71","author":"Srivastava","year":"2019","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.eprac.2022.03.010_bib195","doi-asserted-by":"crossref","first-page":"235","DOI":"10.15403\/jgld-775","article-title":"Identification of patients with advanced fibrosis due to nonalcoholic fatty liver disease: considerations for best practice","volume":"29","author":"Augustin","year":"2020","journal-title":"J\u00a0Gastrointestin Liver Dis"},{"issue":"11","key":"10.1016\/j.eprac.2022.03.010_bib196","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1111\/liv.14198","article-title":"Referral pathways for patients with NAFLD based on non-invasive fibrosis tests: diagnostic accuracy and cost analysis","volume":"39","author":"Crossan","year":"2019","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.eprac.2022.03.010_bib197","doi-asserted-by":"crossref","first-page":"E370","DOI":"10.9778\/cmajo.20200009","article-title":"Risk stratification of patients with nonalcoholic fatty liver disease using a case identification pathway in primary care: a cross-sectional study","volume":"8","author":"Shaheen","year":"2020","journal-title":"CMAJ Open"},{"issue":"1","key":"10.1016\/j.eprac.2022.03.010_bib198","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12876-019-1039-4","article-title":"Cost-comparison analysis of FIB-4, elf and FibroScan in community pathways for non-alcoholic fatty liver disease","volume":"19","author":"Srivastava","year":"2019","journal-title":"BMC Gastroenterol"},{"issue":"11","key":"10.1016\/j.eprac.2022.03.010_bib199","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S2213-8587(16)30162-0","article-title":"Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial","volume":"4","author":"Gregg","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"13","key":"10.1016\/j.eprac.2022.03.010_bib200","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1001\/jama.2019.14231","article-title":"Association of metabolic surgery with major adverse cardiovascular outcomes in patients with type 2 diabetes and obesity","volume":"322","author":"Aminian","year":"2019","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.eprac.2022.03.010_bib201","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.2337\/dc17-2222","article-title":"Global diabetes prevention interventions: a systematic review and network meta-analysis of the real-world impact on incidence, weight, and glucose","volume":"41","author":"Galaviz","year":"2018","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.eprac.2022.03.010_bib202","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"9548","key":"10.1016\/j.eprac.2022.03.010_bib203","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/S0140-6736(06)69701-8","article-title":"Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish diabetes prevention study","volume":"368","author":"Lindstr\u00f6m","year":"2006","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.eprac.2022.03.010_bib204","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S2213-8587(14)70057-9","article-title":"Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study","volume":"2","author":"Li","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"10.1016\/j.eprac.2022.03.010_bib205","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.2337\/dc20-0059","article-title":"Newly discovered abnormal glucose tolerance in patients with acute myocardial infarction and cardiovascular outcomes: a meta-analysis","volume":"43","author":"Laichuthai","year":"2020","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.eprac.2022.03.010_bib206","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.2337\/dc16-0024","volume":"39","year":"2016","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.eprac.2022.03.010_bib207","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.jand.2015.02.031","article-title":"Lifestyle weight-loss intervention outcomes in overweight and obese adults with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials","volume":"115","author":"Franz","year":"2015","journal-title":"J\u00a0Acad Nutr Diet"},{"issue":"15","key":"10.1016\/j.eprac.2022.03.010_bib208","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"9493","key":"10.1016\/j.eprac.2022.03.010_bib209","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"issue":"9976","key":"10.1016\/j.eprac.2022.03.010_bib210","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","article-title":"Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials","volume":"385","author":"Fulcher","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.eprac.2022.03.010_bib211","doi-asserted-by":"crossref","first-page":"i717","DOI":"10.1136\/bmj.i717","article-title":"Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses","volume":"352","author":"Brunstr\u00f6m","year":"2016","journal-title":"BMJ"},{"issue":"10022","key":"10.1016\/j.eprac.2022.03.010_bib212","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","article-title":"Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis","volume":"387","author":"Ettehad","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.eprac.2022.03.010_bib213","doi-asserted-by":"crossref","first-page":"372","DOI":"10.4158\/EP161688.PS","article-title":"Adiposity-based chronic disease as a new diagnostic term: the American Association of Clinical Endocrinologists and American College of Endocrinology position statement","volume":"23","author":"Mechanick","year":"2017","journal-title":"Endocr Pract"},{"issue":"2","key":"10.1016\/j.eprac.2022.03.010_bib214","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000497124","article-title":"The ABCD of obesity: an EASO position statement on a diagnostic term with clinical and scientific implications","volume":"12","author":"Fr\u00fchbeck","year":"2019","journal-title":"Obes Facts"},{"issue":"9","key":"10.1016\/j.eprac.2022.03.010_bib215","doi-asserted-by":"crossref","first-page":"977","DOI":"10.4158\/EP14280.PS","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the 2014 advanced framework for a new diagnosis of obesity as a chronic disease","volume":"20","author":"Garvey","year":"2014","journal-title":"Endocr Pract"},{"issue":"suppl 3","key":"10.1016\/j.eprac.2022.03.010_bib216","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP161365.GL","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity","volume":"22","author":"Garvey","year":"2016","journal-title":"Endocr Pract"},{"issue":"1","key":"10.1016\/j.eprac.2022.03.010_bib217","doi-asserted-by":"crossref","first-page":"91","DOI":"10.4158\/CS-2017-0153","article-title":"Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2018 executive summary","volume":"24","author":"Garber","year":"2018","journal-title":"Endocr Pract"},{"issue":"Suppl 1","key":"10.1016\/j.eprac.2022.03.010_bib218","first-page":"S113","article-title":"Obesity management for the treatment of type 2 diabetes: standards of medical care in diabetes-2022","volume":"45","year":"2022","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"10.1016\/j.eprac.2022.03.010_bib219","first-page":"S39","article-title":"Prevention or delay of type 2 diabetes: standards of medical care in diabetes-2022","volume":"45","year":"2022","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"10.1016\/j.eprac.2022.03.010_bib220","first-page":"S144","article-title":"Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2022","volume":"45","year":"2022","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.eprac.2022.03.010_bib221","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jacc.2019.11.044","article-title":"Cardiometabolic-based chronic disease, adiposity and dysglycemia drivers: JACC state-of-the-art review","volume":"75","author":"Mechanick","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.eprac.2022.03.010_bib222","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S2213-8587(18)30154-2","article-title":"Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies","volume":"7","author":"Stefan","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.eprac.2022.03.010_bib223","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/oby.20585","article-title":"The progression of cardiometabolic disease: validation of a new cardiometabolic disease staging system applicable to obesity","volume":"22","author":"Guo","year":"2014","journal-title":"Obesity (Silver Spring)"},{"issue":"5","key":"10.1016\/j.eprac.2022.03.010_bib224","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1136\/gutjnl-2020-322572","article-title":"Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals","volume":"70","author":"Mantovani","year":"2021","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.eprac.2022.03.010_bib225","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.atherosclerosis.2015.05.002","article-title":"Advanced fibrosis associates with atherosclerosis in subjects with nonalcoholic fatty liver disease","volume":"241","author":"Chen","year":"2015","journal-title":"Atherosclerosis"},{"issue":"12","key":"10.1016\/j.eprac.2022.03.010_bib226","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1136\/gut.2011.242016","article-title":"Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease","volume":"60","author":"Wong","year":"2011","journal-title":"Gut"},{"issue":"7","key":"10.1016\/j.eprac.2022.03.010_bib227","doi-asserted-by":"crossref","first-page":"229","DOI":"10.15585\/mmwr.mm7107a1","article-title":"Advisory committee on immunization practices recommended immunization schedule for adults aged 19 years or older \u2014 United States, 2022","volume":"71","author":"Murthy","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.eprac.2022.03.010_bib228","unstructured":"Centers for Disease Control and Prevention. Liver disease and adult vaccination. Accessed December 17, 2021. https:\/\/www.cdc.gov\/vaccines\/adults\/rec-vac\/health-conditions\/liver-disease.html"},{"issue":"2","key":"10.1016\/j.eprac.2022.03.010_bib229","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jhep.2019.04.013","article-title":"The beneficial effects of Mediterranean diet over low-fat diet may be mediated by decreasing hepatic fat content","volume":"71","author":"Gepner","year":"2019","journal-title":"J\u00a0Hepatol"},{"issue":"10","key":"10.1016\/j.eprac.2022.03.010_bib230","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.2337\/dc10-0856","article-title":"Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes","volume":"33","author":"Lazo","year":"2010","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.eprac.2022.03.010_bib231","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/hep.24242","article-title":"Randomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrahepatic fat in overweight and obese human subjects","volume":"53","author":"Haufe","year":"2011","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.eprac.2022.03.010_bib232","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1001\/jamainternmed.2019.2248","article-title":"Association of weight loss interventions with changes in biomarkers of nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"179","author":"Koutoukidis","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"5","key":"10.1016\/j.eprac.2022.03.010_bib233","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/j.clnu.2018.09.022","article-title":"Critical appraisal for low-carbohydrate diet in nonalcoholic fatty liver disease: review and meta-analyses","volume":"38","author":"Ahn","year":"2019","journal-title":"Clin Nutr"},{"issue":"12","key":"10.1016\/j.eprac.2022.03.010_bib234","doi-asserted-by":"crossref","first-page":"3774","DOI":"10.3390\/nu12123774","article-title":"The effect of low-fat and low-carbohydrate diets on weight loss and lipid levels: a systematic review and meta-analysis","volume":"12","author":"Chawla","year":"2020","journal-title":"Nutrients"},{"issue":"3","key":"10.1016\/j.eprac.2022.03.010_bib235","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/apt.15063","article-title":"Impact of a structured lifestyle programme on patients with metabolic syndrome complicated by non-alcoholic fatty liver disease","volume":"49","author":"Konerman","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.eprac.2022.03.010_bib236","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/j.soard.2019.09.060","article-title":"Systematic review and meta-analysis of Roux-en-y gastric bypass against laparoscopic sleeve gastrectomy for amelioration of NAFLD using four criteria","volume":"15","author":"Baldwin","year":"2019","journal-title":"Surg Obes Relat Dis"},{"issue":"2","key":"10.1016\/j.eprac.2022.03.010_bib237","first-page":"117","article-title":"Intermittent fasting and weight loss: systematic review","volume":"66","author":"Welton","year":"2020","journal-title":"Can Fam Physician"},{"issue":"1","key":"10.1016\/j.eprac.2022.03.010_bib238","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hep.23276","article-title":"Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis","volume":"51","author":"Promrat","year":"2010","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.eprac.2022.03.010_bib239","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.eprac.2022.03.010_bib240","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1002\/hep.28484","article-title":"Development and\u00a0validation of a noninvasive prediction model for nonalcoholic steatohepatitis resolution after lifestyle intervention","volume":"63","author":"Vilar-Gomez","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.eprac.2022.03.010_bib241","doi-asserted-by":"crossref","first-page":"154455","DOI":"10.1016\/j.metabol.2020.154455","article-title":"The effect of the magnitude of weight loss on non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"115","author":"Koutoukidis","year":"2021","journal-title":"Metabolism"},{"issue":"5","key":"10.1016\/j.eprac.2022.03.010_bib242","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.2337\/dc19-2331","article-title":"Intrahepatic fat and postprandial glycemia increase after consumption of a diet enriched in saturated fat compared with free sugars","volume":"43","author":"Parry","year":"2020","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.eprac.2022.03.010_bib243","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.2337\/dc18-0071","article-title":"Saturated fat is more metabolically harmful for the human liver than unsaturated fat or simple sugars","volume":"41","author":"Luukkonen","year":"2018","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.eprac.2022.03.010_bib244","doi-asserted-by":"crossref","first-page":"6207","DOI":"10.1210\/jc.2019-00160","article-title":"Overeating saturated fat promotes fatty liver and ceramides compared with polyunsaturated fat: a randomized trial","volume":"104","author":"Rosqvist","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2022.03.010_bib245","doi-asserted-by":"crossref","first-page":"634344","DOI":"10.3389\/fphar.2021.634344","article-title":"Fructose and non-alcoholic steatohepatitis","volume":"12","author":"Roeb","year":"2021","journal-title":"Front Pharmacol"},{"issue":"10","key":"10.1016\/j.eprac.2022.03.010_bib246","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.3390\/nu11102543","article-title":"The metabolic and hepatic impact of two personalized dietary strategies in subjects with obesity and nonalcoholic fatty liver disease: the Fatty Liver in Obesity (FLIO) randomized controlled trial","volume":"11","author":"Marin-Alejandre","year":"2019","journal-title":"Nutrients"},{"issue":"1","key":"10.1016\/j.eprac.2022.03.010_bib247","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1053\/j.gastro.2018.03.038","article-title":"Improved diet quality associates with reduction in liver fat, particularly in individuals with high genetic risk scores for nonalcoholic fatty liver disease","volume":"155","author":"Ma","year":"2018","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.eprac.2022.03.010_bib248","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1007\/s12603-016-0809-8","article-title":"Effect of a low glycemic index Mediterranean diet on non-alcoholic fatty liver disease. A randomized controlled clinici trial","volume":"21","author":"Misciagna","year":"2017","journal-title":"J\u00a0Nutr Health Aging"},{"issue":"4","key":"10.1016\/j.eprac.2022.03.010_bib249","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jhep.2017.05.016","article-title":"Treatment of NAFLD with diet, physical activity and exercise","volume":"67","author":"Romero-G\u00f3mez","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.eprac.2022.03.010_bib250","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jhep.2013.02.012","article-title":"The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease","volume":"59","author":"Ryan","year":"2013","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.eprac.2022.03.010_bib251","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1002\/hep.30076","article-title":"Ad libitum Mediterranean and low-fat diets both significantly reduce hepatic steatosis: a randomized controlled trial","volume":"68","author":"Properzi","year":"2018","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.eprac.2022.03.010_bib252","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1055\/s-0041-1723751","article-title":"Effects of Mediterranean diet in patients with nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression analysis of randomized controlled trials","volume":"41","author":"Kawaguchi","year":"2021","journal-title":"Semin Liver Dis"},{"issue":"4","key":"10.1016\/j.eprac.2022.03.010_bib253","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/liv.12990","article-title":"The effects of DASH diet on weight loss and metabolic status in adults with non-alcoholic fatty liver disease: a randomized clinical trial","volume":"36","author":"Razavi Zade","year":"2016","journal-title":"Liver Int"},{"issue":"6","key":"10.1016\/j.eprac.2022.03.010_bib254","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.eprac.2022.03.010_bib255","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.clnu.2018.12.022","article-title":"ESPEN guideline on clinical nutrition in liver disease","volume":"38","author":"Plauth","year":"2019","journal-title":"Clin Nutr"},{"issue":"6","key":"10.1016\/j.eprac.2022.03.010_bib256","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s12072-020-10094-2","article-title":"The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease","volume":"14","author":"Eslam","year":"2020","journal-title":"Hepatol Int"},{"issue":"6","key":"10.1016\/j.eprac.2022.03.010_bib257","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.aohep.2020.09.006","article-title":"Latin American Association for the Study of the Liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease","volume":"19","author":"Arab","year":"2020","journal-title":"Ann Hepatol"},{"issue":"3","key":"10.1016\/j.eprac.2022.03.010_bib258","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1053\/j.gastro.2020.11.051","article-title":"AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: expert review","volume":"160","author":"Younossi","year":"2021","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.eprac.2022.03.010_bib259","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1111\/liv.14596","article-title":"High-protein diet more effectively reduces hepatic fat than low-protein diet despite lower autophagy and FGF21 levels","volume":"40","author":"Xu","year":"2020","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.eprac.2022.03.010_bib260","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1053\/j.gastro.2016.10.007","article-title":"Isocaloric diets high in animal or plant protein reduce liver fat and inflammation in individuals with type 2 diabetes","volume":"152","author":"Markova","year":"2017","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.eprac.2022.03.010_bib261","doi-asserted-by":"crossref","first-page":"11232","DOI":"10.1038\/s41598-019-47763-8","article-title":"A\u00a0randomised controlled trial on the effectiveness and adherence of modified alternate-day calorie restriction in improving activity of non-alcoholic fatty liver disease","volume":"9","author":"Johari","year":"2019","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.eprac.2022.03.010_bib262","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s12876-019-1132-8","article-title":"Effects of alternate-day fasting on body weight and dyslipidaemia in patients with non-alcoholic fatty liver disease: a randomised controlled trial","volume":"19","author":"Cai","year":"2019","journal-title":"BMC Gastroenterol"},{"issue":"3","key":"10.1016\/j.eprac.2022.03.010_bib263","doi-asserted-by":"crossref","first-page":"100256","DOI":"10.1016\/j.jhepr.2021.100256","article-title":"Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet - a randomised controlled trial","volume":"3","author":"Holmer","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1016\/j.eprac.2022.03.010_bib264","doi-asserted-by":"crossref","first-page":"709683","DOI":"10.3389\/fnut.2021.709683","article-title":"Effect of intermittent fasting on non-alcoholic fatty liver disease: systematic review and meta-analysis","volume":"8","author":"Yin","year":"2021","journal-title":"Front Nutr"},{"issue":"9","key":"10.1016\/j.eprac.2022.03.010_bib265","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1136\/gut.2011.242073","article-title":"Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss","volume":"60","author":"Hallsworth","year":"2011","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.eprac.2022.03.010_bib266","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1002\/hep.25548","article-title":"Randomized trial of exercise effect on intrahepatic triglyceride content and lipid kinetics in nonalcoholic fatty liver disease","volume":"55","author":"Sullivan","year":"2012","journal-title":"Hepatology"},{"issue":"27","key":"10.1016\/j.eprac.2022.03.010_bib267","doi-asserted-by":"crossref","first-page":"6318","DOI":"10.3748\/wjg.v22.i27.6318","article-title":"Effectiveness of exercise in hepatic fat mobilization in non-alcoholic fatty liver disease: systematic review","volume":"22","author":"Golabi","year":"2016","journal-title":"World J Gastroenterol"},{"issue":"10","key":"10.1016\/j.eprac.2022.03.010_bib268","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.cgh.2016.04.036","article-title":"Exercise-based interventions for nonalcoholic fatty liver disease: a meta-analysis and meta-regression","volume":"14","author":"Orci","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.eprac.2022.03.010_bib269","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s00421-018-3818-y","article-title":"Effects of sprint interval training on ectopic lipids and tissue-specific insulin sensitivity in men with non-alcoholic fatty liver disease","volume":"118","author":"Sargeant","year":"2018","journal-title":"Eur J Appl Physiol"},{"issue":"2","key":"10.1016\/j.eprac.2022.03.010_bib270","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1042\/CS20150447","article-title":"Dissociation between exercise-induced reduction in liver fat and changes in hepatic and peripheral glucose homoeostasis in obese patients with non-alcoholic fatty liver disease","volume":"130","author":"Cuthbertson","year":"2016","journal-title":"Clin Sci (Lond)"},{"issue":"1","key":"10.1016\/j.eprac.2022.03.010_bib271","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jhep.2015.02.022","article-title":"Effect of aerobic exercise training dose on liver fat and visceral adiposity","volume":"63","author":"Keating","year":"2015","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.eprac.2022.03.010_bib272","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.cgh.2016.07.031","article-title":"Exercise reduces liver lipids and visceral adiposity in patients with nonalcoholic steatohepatitis in a randomized controlled trial","volume":"15","author":"Houghton","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.eprac.2022.03.010_bib273","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1111\/apt.15989","article-title":"Improvement in histological endpoints of MAFLD following a 12-week aerobic exercise intervention","volume":"52","author":"O'Gorman","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.eprac.2022.03.010_bib274","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1111\/obr.12719","article-title":"The effect of exercise training on intrahepatic triglyceride and hepatic insulin sensitivity: a systematic review and meta-analysis","volume":"19","author":"Sargeant","year":"2018","journal-title":"Obes Rev"},{"issue":"8","key":"10.1016\/j.eprac.2022.03.010_bib275","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1001\/jamainternmed.2016.3202","article-title":"Effects of moderate and vigorous exercise on nonalcoholic fatty liver disease: a randomized clinical trial","volume":"176","author":"Zhang","year":"2016","journal-title":"JAMA Intern Med"},{"issue":"1","key":"10.1016\/j.eprac.2022.03.010_bib276","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jhep.2016.08.023","article-title":"Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: a systematic review","volume":"66","author":"Hashida","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.eprac.2022.03.010_bib277","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.metabol.2017.08.012","article-title":"Energy-matched moderate and high intensity exercise training improves nonalcoholic fatty liver disease risk independent of changes in body mass or abdominal adiposity - a randomized trial","volume":"78","author":"Winn","year":"2018","journal-title":"Metabolism"},{"issue":"3","key":"10.1016\/j.eprac.2022.03.010_bib278","doi-asserted-by":"crossref","first-page":"100253","DOI":"10.1016\/j.jhepr.2021.100253","article-title":"Weight-loss-independent benefits of exercise on liver steatosis and stiffness in Japanese men with NAFLD","volume":"3","author":"Oh","year":"2021","journal-title":"JHEP Rep"},{"issue":"17","key":"10.1016\/j.eprac.2022.03.010_bib279","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"Prospective study of outcomes in adults with nonalcoholic fatty liver disease","volume":"385","author":"Sanyal","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.eprac.2022.03.010_bib280","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A\u00a0placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis","volume":"355","author":"Belfort","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.eprac.2022.03.010_bib281","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1053\/j.gastro.2008.06.047","article-title":"Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis","volume":"135","author":"Aithal","year":"2008","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.eprac.2022.03.010_bib282","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2337\/dc19-0167","article-title":"Role of vitamin E for nonalcoholic steatohepatitis in patients with type 2 diabetes: a randomized controlled trial","volume":"42","author":"Bril","year":"2019","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.eprac.2022.03.010_bib283","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/jamainternmed.2016.9607","article-title":"Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis","volume":"177","author":"Musso","year":"2017","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.eprac.2022.03.010_bib284","author":"Rind"},{"issue":"4","key":"10.1016\/j.eprac.2022.03.010_bib285","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s13300-017-0273-4","article-title":"Pioglitazone and the risk of bladder cancer: a meta-analysis","volume":"8","author":"Filipova","year":"2017","journal-title":"Diabetes Ther"},{"issue":"6","key":"10.1016\/j.eprac.2022.03.010_bib286","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1002\/hep.30670","article-title":"Incretin-based therapies for the management of nonalcoholic fatty liver disease in patients with type 2 diabetes","volume":"69","author":"Cusi","year":"2019","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.eprac.2022.03.010_bib287","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1210\/clinem\/dgab578","article-title":"The emerging role of glucagon-like peptide-1 receptor agonists for the management of NAFLD","volume":"107","author":"Patel Chavez","year":"2022","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"10019","key":"10.1016\/j.eprac.2022.03.010_bib288","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (lean): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.eprac.2022.03.010_bib289","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"issue":"14","key":"10.1016\/j.eprac.2022.03.010_bib290","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial","volume":"325","author":"Wadden","year":"2021","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.eprac.2022.03.010_bib291","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"10278","key":"10.1016\/j.eprac.2022.03.010_bib292","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (step 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.eprac.2022.03.010_bib293","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41574-020-0392-2","article-title":"Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus","volume":"16","author":"Scheen","year":"2020","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"10.1016\/j.eprac.2022.03.010_bib294","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2337\/dci19-0064","article-title":"Time to include nonalcoholic steatohepatitis in the management of patients with type 2 diabetes","volume":"43","author":"Cusi","year":"2020","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.eprac.2022.03.010_bib295","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/dom.13584","article-title":"Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes","volume":"21","author":"Cusi","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"10.1016\/j.eprac.2022.03.010_bib296","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2337\/dc18-1569","article-title":"The SGLT2 inhibitor dapagliflozin reduces liver fat but does not affect tissue insulin sensitivity: a randomized, double-blind, placebo-controlled study with 8-week treatment in type 2 diabetes patients","volume":"42","author":"Latva-Rasku","year":"2019","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.eprac.2022.03.010_bib297","doi-asserted-by":"crossref","first-page":"298","DOI":"10.2337\/dc19-0641","article-title":"Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial","volume":"43","author":"Kahl","year":"2020","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.eprac.2022.03.010_bib298","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1365-2036.2008.03869.x","article-title":"Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis","volume":"29","author":"Loomba","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.eprac.2022.03.010_bib299","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/j.1572-0241.2005.41583.x","article-title":"A\u00a0randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease","volume":"100","author":"Bugianesi","year":"2005","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.eprac.2022.03.010_bib300","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s00125-011-2446-4","article-title":"Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials","volume":"55","author":"Musso","year":"2012","journal-title":"Diabetologia"},{"issue":"32","key":"10.1016\/j.eprac.2022.03.010_bib301","doi-asserted-by":"crossref","first-page":"e4529","DOI":"10.1097\/MD.0000000000004529","article-title":"Comparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD): a prisma-compliant systematic review and network meta-analysis","volume":"95","author":"Sawangjit","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.eprac.2022.03.010_bib302","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3892\/br.2012.18","article-title":"Metformin in non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"1","author":"Li","year":"2013","journal-title":"Biomed Rep"},{"issue":"12","key":"10.1016\/j.eprac.2022.03.010_bib303","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1007\/s00125-016-4100-7","article-title":"Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial","volume":"59","author":"Smits","year":"2016","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.eprac.2022.03.010_bib304","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3748\/wjg.v23.i1.141","article-title":"Sitagliptin in patients with non-alcoholic steatohepatitis: a randomized, placebo-controlled trial","volume":"23","author":"Joy","year":"2017","journal-title":"World J Gastroenterol"},{"issue":"2","key":"10.1016\/j.eprac.2022.03.010_bib305","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jhep.2016.04.021","article-title":"Sitagliptin vs. placebo for non-alcoholic fatty\u00a0liver disease: a randomized controlled trial","volume":"65","author":"Cui","year":"2016","journal-title":"J\u00a0Hepatol"},{"issue":"suppl 2","key":"10.1016\/j.eprac.2022.03.010_bib306","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/dom.12751","article-title":"Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes","volume":"18","author":"Cusi","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.eprac.2022.03.010_bib307","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/hep.30368","article-title":"Vitamin E improves transplant-free survival and hepatic decompensation among patients with nonalcoholic steatohepatitis and advanced fibrosis","volume":"71","author":"Vilar-Gomez","year":"2020","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.eprac.2022.03.010_bib308","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.metabol.2016.04.004","article-title":"Pharmacological management of nonalcoholic fatty liver disease","volume":"65","author":"Barb","year":"2016","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.eprac.2022.03.010_bib309","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/hep.23623","article-title":"A\u00a0meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease","volume":"52","author":"Musso","year":"2010","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.eprac.2022.03.010_bib310","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1053\/j.gastro.2017.12.024","article-title":"Effects of weight-loss medications on cardiometabolic risk profiles: a systematic review and network meta-analysis","volume":"154","author":"Khera","year":"2018","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.eprac.2022.03.010_bib311","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1002\/oby.21629","article-title":"Early weight loss with liraglutide 3.0 mg predicts 1-year weight loss and is associated with improvements in clinical markers","volume":"24","author":"Fujioka","year":"2016","journal-title":"Obesity (Silver Spring)"},{"issue":"1","key":"10.1016\/j.eprac.2022.03.010_bib312","first-page":"90","article-title":"Efficacy of orlistat in non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"9","author":"Wang","year":"2018","journal-title":"Biomed Rep"},{"issue":"1","key":"10.1016\/j.eprac.2022.03.010_bib313","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/hep.22575","article-title":"Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial","volume":"49","author":"Harrison","year":"2009","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.eprac.2022.03.010_bib314","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.cgh.2006.02.004","article-title":"A\u00a0double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease","volume":"4","author":"Zelber-Sagi","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.eprac.2022.03.010_bib315","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/dom.14284","article-title":"Extended-release naltrexone\/bupropion and liver health: pooled, post hoc analysis from four randomized controlled trials","volume":"23","author":"Bajaj","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"10.1016\/j.eprac.2022.03.010_bib316","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.2337\/dc14-0930","article-title":"Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release","volume":"37","author":"Garvey","year":"2014","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.eprac.2022.03.010_bib317","doi-asserted-by":"crossref","first-page":"912","DOI":"10.2337\/dc13-1518","article-title":"Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release","volume":"37","author":"Garvey","year":"2014","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.eprac.2022.03.010_bib318","doi-asserted-by":"crossref","first-page":"856","DOI":"10.2337\/dc17-0088","article-title":"Cardiometabolic disease staging predicts effectiveness of weight-loss therapy to prevent type 2 diabetes: pooled results from phase III clinical trials assessing phentermine\/topiramate extended release","volume":"40","author":"Guo","year":"2017","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.eprac.2022.03.010_bib319","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.eprac.2022.03.010_bib320","first-page":"891","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"376","author":"Marso","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.eprac.2022.03.010_bib321","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12933-020-01070-z","article-title":"Indirect comparison of glucagon like peptide-1 receptor agonists regarding cardiovascular safety and mortality in patients with type 2 diabetes mellitus: network meta-analysis","volume":"19","author":"Alfayez","year":"2020","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.eprac.2022.03.010_bib322","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ijcard.2014.02.026","article-title":"Bariatric surgery and its impact on cardiovascular disease and mortality: a systematic review and meta-analysis","volume":"173","author":"Kwok","year":"2014","journal-title":"Int J Cardiol"},{"issue":"20","key":"10.1016\/j.eprac.2022.03.010_bib323","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1001\/jama.2021.19569","article-title":"Association of bariatric surgery with major adverse liver and cardiovascular outcomes in patients with biopsy-proven nonalcoholic steatohepatitis","volume":"326","author":"Aminian","year":"2021","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.eprac.2022.03.010_bib324","doi-asserted-by":"crossref","first-page":"74","DOI":"10.7326\/M21-1962","article-title":"Gastric bypass versus sleeve gastrectomy in type 2 diabetes: effects on hepatic steatosis and fibrosis: a randomized controlled trial","volume":"175","author":"Seeberg","year":"2022","journal-title":"Ann Intern Med"},{"issue":"12","key":"10.1016\/j.eprac.2022.03.010_bib325","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/S2213-8587(19)30344-4","article-title":"Gastric bypass versus sleeve gastrectomy in patients with type 2 diabetes (oseberg): a single-centre, triple-blind, randomised controlled trial","volume":"7","author":"Hofs\u00f8","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.eprac.2022.03.010_bib326","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1053\/j.gastro.2015.04.014","article-title":"Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients","volume":"149","author":"Lassailly","year":"2015","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.eprac.2022.03.010_bib327","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1053\/j.gastro.2020.06.006","article-title":"Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis","volume":"159","author":"Lassailly","year":"2020","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.eprac.2022.03.010_bib328","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/ijo.2016.212","article-title":"Safety and efficacy of bariatric surgery in patients with advanced fibrosis","volume":"41","author":"Singh","year":"2017","journal-title":"Int J Obes (Lond)"},{"issue":"5","key":"10.1016\/j.eprac.2022.03.010_bib329","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jceh.2021.01.005","article-title":"The clinical impact of cirrhosis on the hospital outcomes of patients admitted with influenza infection: propensity score matched analysis of 2011-2017 US hospital data","volume":"11","author":"Lee","year":"2021","journal-title":"J\u00a0Clin Exp Hepatol"},{"issue":"3","key":"10.1016\/j.eprac.2022.03.010_bib330","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1001\/jama.2017.20813","article-title":"Lifestyle intervention and medical management with vs without Roux-en-Y gastric bypass and control of hemoglobin A1c, LDL cholesterol, and systolic blood pressure at 5 years in the Diabetes Surgery Study","volume":"319","author":"Ikramuddin","year":"2018","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.eprac.2022.03.010_bib331","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jamcollsurg.2012.12.019","article-title":"Bariatric surgery is associated with a reduction in major macrovascular and microvascular complications in moderately to severely obese patients with type 2 diabetes mellitus","volume":"216","author":"Johnson","year":"2013","journal-title":"J\u00a0Am Coll Surg"},{"issue":"5","key":"10.1016\/j.eprac.2022.03.010_bib332","article-title":"Gastric bypass surgery produces a durable reduction in cardiovascular disease risk factors and reduces the long-term risks of congestive heart failure","volume":"6","author":"Benotti","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"9","key":"10.1016\/j.eprac.2022.03.010_bib333","doi-asserted-by":"crossref","first-page":"694","DOI":"10.7326\/M19-3925","article-title":"Association between bariatric surgery and all-cause mortality: a population-based matched cohort study in a universal health care system","volume":"173","author":"Doumouras","year":"2020","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.eprac.2022.03.010_bib334","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.3390\/nu13103568","article-title":"Reduction of major adverse cardiovascular events (MACE) after bariatric surgery in patients with obesity and cardiovascular diseases: a systematic review and meta-analysis","volume":"13","author":"Sutanto","year":"2021","journal-title":"Nutrients"},{"issue":"4","key":"10.1016\/j.eprac.2022.03.010_bib335","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.gie.2012.05.023","article-title":"Intragastric balloon significantly improves nonalcoholic fatty liver disease activity score in obese patients with nonalcoholic steatohepatitis: a pilot study","volume":"76","author":"Lee","year":"2012","journal-title":"Gastrointest Endosc"},{"issue":"1","key":"10.1016\/j.eprac.2022.03.010_bib336","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.cgh.2020.04.068","article-title":"Intragastric balloon placement induces significant metabolic and histologic improvement in patients with nonalcoholic steatohepatitis","volume":"19","author":"Bazerbachi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.eprac.2022.03.010_bib337","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.gie.2020.09.021","article-title":"Association for bariatric endoscopy systematic review and meta-analysis assessing the American Society for Gastrointestinal Endoscopy preservation and incorporation of valuable endoscopic innovations thresholds for aspiration therapy","volume":"93","author":"Jirapinyo","year":"2021","journal-title":"Gastrointest Endosc"},{"issue":"3","key":"10.1016\/j.eprac.2022.03.010_bib338","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.cgh.2021.03.017","article-title":"Effect of endoscopic bariatric and metabolic therapies on nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"20","author":"Jirapinyo","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.eprac.2022.03.010_bib339","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1007\/s11695-017-3096-5","article-title":"Aspiration therapy as a tool to treat obesity: 1- to 4-year results in a 201-patient multi-center post-market European registry study","volume":"28","author":"Nystr\u00f6m","year":"2018","journal-title":"Obes Surg"},{"issue":"5","key":"10.1016\/j.eprac.2022.03.010_bib340","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.cgh.2020.09.055","article-title":"Five-year outcomes of endoscopic sleeve gastroplasty for the treatment of obesity","volume":"19","author":"Sharaiha","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.eprac.2022.03.010_bib341","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/MPG.0000000000001482","volume":"64","author":"Vos","year":"2017","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"issue":"8","key":"10.1016\/j.eprac.2022.03.010_bib342","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.2337\/dc10-0284","article-title":"Central role of fatty liver in the pathogenesis of insulin resistance in obese adolescents","volume":"33","author":"D'Adamo","year":"2010","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.eprac.2022.03.010_bib343","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/hep.26610","article-title":"Left ventricular dysfunction in obese children and adolescents with nonalcoholic fatty liver disease","volume":"59","author":"Pacifico","year":"2014","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.eprac.2022.03.010_bib344","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.jpeds.2012.08.043","article-title":"Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents, 1988-1994 to 2007-2010","volume":"162","author":"Welsh","year":"2013","journal-title":"J\u00a0Pediatr"},{"issue":"5","key":"10.1016\/j.eprac.2022.03.010_bib345","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.jpeds.2012.11.017","article-title":"Intrahepatic fat is increased in the neonatal offspring of obese women with gestational diabetes","volume":"162","author":"Brumbaugh","year":"2013","journal-title":"J\u00a0Pediatr"},{"issue":"3","key":"10.1016\/j.eprac.2022.03.010_bib346","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1203\/PDR.0b013e318225f9b1","article-title":"The influence of maternal body mass index on infant adiposity and hepatic lipid content","volume":"70","author":"Modi","year":"2011","journal-title":"Pediatr Res"},{"issue":"2","key":"10.1016\/j.eprac.2022.03.010_bib347","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/MPG.0000000000000520","article-title":"Hepatic steatosis is prevalent in stillborns delivered to women with diabetes mellitus","volume":"60","author":"Patel","year":"2015","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"issue":"10","key":"10.1016\/j.eprac.2022.03.010_bib348","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140908","article-title":"The prevalence of non-alcoholic fatty liver disease in children and adolescents: a systematic review and meta-analysis","volume":"10","author":"Anderson","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.eprac.2022.03.010_bib349","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/01.MPG.0000164698.03164.E5","article-title":"Type 2 diabetes in children is frequently associated with elevated alanine aminotransferase","volume":"41","author":"Nadeau","year":"2005","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.eprac.2022.03.010_bib350","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/1471-2431-12-174","article-title":"Ethnicity and elevated liver transaminases among newly diagnosed children with type 2 diabetes","volume":"12","author":"Hudson","year":"2012","journal-title":"BMC Pediatr"},{"issue":"5","key":"10.1016\/j.eprac.2022.03.010_bib351","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/jgh.13241","article-title":"Adverse metabolic phenotype of adolescent girls with non-alcoholic fatty liver disease plus polycystic ovary syndrome compared with other girls and boys","volume":"31","author":"Ayonrinde","year":"2016","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.eprac.2022.03.010_bib352","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/obr.12904","article-title":"A\u00a0systematic review and meta-analysis estimating the population prevalence of comorbidities in children and adolescents aged 5 to 18 years","volume":"20","author":"Sharma","year":"2019","journal-title":"Obes Rev"},{"issue":"1","key":"10.1016\/j.eprac.2022.03.010_bib353","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12933-020-01052-1","article-title":"Cardiovascular morbidity, diabetes and cancer risk among children and adolescents with severe obesity","volume":"19","author":"Bendor","year":"2020","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"10.1016\/j.eprac.2022.03.010_bib354","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00431-017-2876-1","article-title":"Screening for non-alcoholic fatty liver disease in children and adolescents with type 1 diabetes mellitus: a cross-sectional analysis","volume":"176","author":"Kummer","year":"2017","journal-title":"Eur J Pediatr"},{"issue":"8","key":"10.1016\/j.eprac.2022.03.010_bib355","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.metabol.2015.04.002","article-title":"Magnetic resonance imaging reveals altered distribution of hepatic fat in children with type 1 diabetes compared to controls","volume":"64","author":"Regnell","year":"2015","journal-title":"Metabolism"},{"issue":"5","key":"10.1016\/j.eprac.2022.03.010_bib356","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1053\/j.gastro.2020.07.034","article-title":"Progression of fatty liver disease in children receiving standard of care lifestyle advice","volume":"159","author":"Xanthakos","year":"2020","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.eprac.2022.03.010_bib357","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1053\/j.gastro.2016.08.027","article-title":"In children with nonalcoholic fatty liver disease, cysteamine bitartrate delayed release improves liver enzymes but does not reduce disease activity scores","volume":"151","author":"Schwimmer","year":"2016","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.eprac.2022.03.010_bib358","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/oby.20173","article-title":"Accuracy of prediction scores and novel biomarkers for predicting nonalcoholic fatty liver disease in obese children","volume":"21","author":"Koot","year":"2013","journal-title":"Obesity (Silver Spring)"},{"issue":"39","key":"10.1016\/j.eprac.2022.03.010_bib359","doi-asserted-by":"crossref","first-page":"8812","DOI":"10.3748\/wjg.v22.i39.8812","article-title":"Comparison of magnetic resonance spectroscopy, proton density fat fraction and histological analysis in the quantification of liver steatosis in children and adolescents","volume":"22","author":"Di Martino","year":"2016","journal-title":"World J Gastroenterol"},{"issue":"3","key":"10.1016\/j.eprac.2022.03.010_bib360","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/hep.29596","article-title":"Diagnostic accuracy of magnetic resonance imaging hepatic proton density fat fraction in pediatric nonalcoholic fatty liver disease","volume":"67","author":"Middleton","year":"2018","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.eprac.2022.03.010_bib361","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1002\/hep.27666","article-title":"Magnetic resonance imaging and liver histology as biomarkers of hepatic steatosis in children with nonalcoholic fatty liver disease","volume":"61","author":"Schwimmer","year":"2015","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.eprac.2022.03.010_bib362","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.3748\/wjg.v25.i12.1513","article-title":"Accuracy of multi-echo dixon sequence in quantification of hepatic steatosis in Chinese children and adolescents","volume":"25","author":"Zhao","year":"2019","journal-title":"World J Gastroenterol"},{"issue":"4","key":"10.1016\/j.eprac.2022.03.010_bib363","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2020-009829","article-title":"Alternative etiologies of liver disease in children with suspected NAFLD","volume":"147","author":"Yodoshi","year":"2021","journal-title":"Pediatrics"},{"issue":"5","key":"10.1016\/j.eprac.2022.03.010_bib364","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.cgh.2013.09.050","article-title":"Evidence and recommendations for imaging liver fat in children, based on systematic review","volume":"12","author":"Awai","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.eprac.2022.03.010_bib365","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1007\/s00261-015-0542-5","article-title":"Intra- and inter-examination repeatability of magnetic resonance spectroscopy, magnitude-based MRI, and complex-based mri for estimation of hepatic proton density fat fraction in overweight and obese children and adults","volume":"40","author":"Tyagi","year":"2015","journal-title":"Abdom Imaging"},{"issue":"5","key":"10.1016\/j.eprac.2022.03.010_bib366","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1007\/s10620-014-3494-7","article-title":"The evaluation of hepatic fibrosis scores in children with nonalcoholic fatty liver disease","volume":"60","author":"Mansoor","year":"2015","journal-title":"Dig Dis Sci"},{"issue":"2","key":"10.1016\/j.eprac.2022.03.010_bib367","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/MPG.0000000000001136","article-title":"Plasma cytokeratin-18 level as a novel biomarker for liver fibrosis in children with nonalcoholic fatty liver disease","volume":"63","author":"Mandelia","year":"2016","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"issue":"5","key":"10.1016\/j.eprac.2022.03.010_bib368","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1002\/hep.29241","article-title":"Magnetic resonance elastography measured shear stiffness as a biomarker of fibrosis in pediatric nonalcoholic fatty liver disease","volume":"66","author":"Schwimmer","year":"2017","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.eprac.2022.03.010_bib369","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/liv.12024","article-title":"Combined paediatric NAFLD fibrosis index and transient elastography to predict clinically significant fibrosis in children with fatty liver disease","volume":"33","author":"Alkhouri","year":"2013","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.eprac.2022.03.010_bib370","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1097\/MPG.0000000000002991","article-title":"Performance characteristics, intra- and inter-operator agreement of transient elastography in pediatric nonalcoholic fatty liver disease","volume":"72","author":"Mandelia","year":"2021","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"issue":"1","key":"10.1016\/j.eprac.2022.03.010_bib371","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/MPG.0b013e31826f2760","article-title":"Transient elastography is a useful noninvasive tool for the evaluation of fibrosis in paediatric chronic liver disease","volume":"56","author":"Fitzpatrick","year":"2013","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"issue":"2","key":"10.1016\/j.eprac.2022.03.010_bib372","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/hep.22376","article-title":"Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis","volume":"48","author":"Nobili","year":"2008","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.eprac.2022.03.010_bib373","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1001\/jama.2018.20579","article-title":"Effect of a low free sugar diet vs usual diet on nonalcoholic fatty liver disease in adolescent boys: a randomized clinical trial","volume":"321","author":"Schwimmer","year":"2019","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.eprac.2022.03.010_bib374","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.2337\/db12-0214","article-title":"Effects of aerobic versus resistance exercise without caloric restriction on abdominal fat, intrahepatic lipid, and insulin sensitivity in obese adolescent boys: a randomized, controlled trial","volume":"61","author":"Lee","year":"2012","journal-title":"Diabetes"},{"issue":"16","key":"10.1016\/j.eprac.2022.03.010_bib375","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1001\/jama.2011.520","article-title":"Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the tonic randomized controlled trial","volume":"305","author":"Lavine","year":"2011","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.eprac.2022.03.010_bib376","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/j.cgh.2018.05.023","article-title":"Evaluations of lifestyle, dietary,\u00a0and pharmacologic treatments for pediatric nonalcoholic fatty liver disease: a systematic review","volume":"17","author":"Mann","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.eprac.2022.03.010_bib377","doi-asserted-by":"crossref","DOI":"10.1111\/ijpo.12495","article-title":"Liraglutide effects in a paediatric (7-11 y) population with obesity: a randomized, double-blind, placebo-controlled, short-term trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics","volume":"14","author":"Mastrandrea","year":"2019","journal-title":"Pediatr Obes"},{"key":"10.1016\/j.eprac.2022.03.010_bib378","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jpeds.2016.10.076","article-title":"Liraglutide in an adolescent population with obesity: a randomized, double-blind, placebo-controlled 5-week trial to assess safety, tolerability, and pharmacokinetics of liraglutide in adolescents aged 12-17 years","volume":"181","author":"Danne","year":"2017","journal-title":"J\u00a0Pediatr"},{"issue":"6","key":"10.1016\/j.eprac.2022.03.010_bib379","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s40262-014-0229-z","article-title":"Comparable liraglutide pharmacokinetics in pediatric and adult populations with type 2 diabetes: a population pharmacokinetic analysis","volume":"54","author":"Petri","year":"2015","journal-title":"Clin Pharmacokinet"},{"issue":"22","key":"10.1016\/j.eprac.2022.03.010_bib380","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1916038","article-title":"A\u00a0randomized, controlled trial of liraglutide for adolescents with obesity","volume":"382","author":"Kelly","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.eprac.2022.03.010_bib381","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1056\/NEJMoa1903822","article-title":"Liraglutide in children and adolescents with type 2 diabetes","volume":"381","author":"Tamborlane","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.eprac.2022.03.010_bib383","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2015-1766","article-title":"Physical examination findings among children and adolescents with obesity: an evidence-based review","volume":"137","author":"Armstrong","year":"2016","journal-title":"Pediatrics"},{"issue":"22","key":"10.1016\/j.eprac.2022.03.010_bib384","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1056\/NEJMoa1813909","article-title":"Five-year outcomes of gastric bypass in adolescents as compared with adults","volume":"380","author":"Inge","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eprac.2022.03.010_bib385","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jpeds.2016.08.101","article-title":"The benefit of sleeve gastrectomy in obese adolescents on nonalcoholic steatohepatitis and hepatic fibrosis","volume":"180","author":"Manco","year":"2017","journal-title":"J\u00a0Pediatr"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X22000908?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X22000908?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:13:14Z","timestamp":1761516794000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X22000908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":384,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S1530891X22000908"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2022.03.010","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2022.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc. on behalf of the AACE.","name":"copyright","label":"Copyright"}]}}